title: A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
abstract: During the past decade, the treatment of lung adenocarcinomas has been revolutionized with novel molecular targeted therapies. We describe a case of clinical activity of crizotinib in a female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial response was observed in this 67 year-old woman. Further clinical trials of crizotinib are needed for non-small cell lung cancer exhibiting MET mutations.
authors.affiliation: Drug development Department (DITEP), Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France. linda.mahjoubi@gustaveroussy.fr.|University Paris-Sud, Villejuif, France. linda.mahjoubi@gustaveroussy.fr.
authors.forename: Linda
authors.initials: L
authors.lastname: Mahjoubi
authors.affiliation: Drug development Department (DITEP), Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.|University Paris-Sud, Villejuif, France.
authors.forename: Anas
authors.initials: A
authors.lastname: Gazzah
authors.affiliation: Translational Research Laboratory and BioBank, Gustave Roussy, Villejuif, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.affiliation: INSERM U981, Gustave Roussy, University Paris XI, Villejuif, France.|Department of Medical Biology and Pathology, Gustave Roussy, University Paris XI, Villejuif, France.
authors.forename: Ludovic
authors.initials: L
authors.lastname: Lacroix
authors.affiliation: Drug development Department (DITEP), Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.|University Paris-Sud, Villejuif, France.|Department of Medical Biology and Pathology, Gustave Roussy, University Paris XI, Villejuif, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000077547:Crizotinib; D005091:Exons; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met
keywords: Crizotinib; Exon 14 mutation; MET; NGS; NSCLC